Perlegen Sciences, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Perlegen Sciences, Inc.
Private Company Edition: Genesis raised $200m, Rapport brought in $150m and Cellares closed a $255m round. Also, Ferring got $300m up front in a royalty deal, Fore Biotherapeutics raised a $75m series D and Vaxxas won a $3.67m Wellcome grant to advance a next-generation typhoid vaccine.
Restructuring Edition: FibroGen follows its clinical setback with a 32% reduction in force, cutting 104 jobs. Also, Amarin named a new CEO, but cut all US sales and 30% of non-sales US roles, and 9 Meters is headed for dissolution after Chapter 7 bankruptcy, while several others seek strategic alternatives.
The biggest barrier for Eisai/Biogen’s Alzheimer’s medicine Leqembi was Medicare. With full US FDA approval and Medicare coverage in place, PET scan, MRI and infusion centers are needed to facilitate treatment.
Private Company Edition: In the first week of April, Cure Ventures launched with a $350m fund, the Alzheimer’s Drug Discovery Fund received $200m for its venture philanthropy strategy and Canaan revealed $850m in new funds. Also, OnKure raised $53.7m and Phlow closed a $36m series B round.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.